Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGP 15

Next Previous
Drug Profile

BGP 15

Alternative Names: BGP-15

Latest Information Update: 04 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator N-Gene Research Laboratories
  • Developer Allos Therapeutics; Mitochon Technologies; N-Gene Research Laboratories; Sinusventure; University of Melbourne
  • Class Antihyperglycaemics; Oximes; Piperidines; Small molecules
  • Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors; Oxygen radical formation antagonists; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Insulin resistance; Sinus tachycardia
  • Phase I Familial dysautonomia
  • No development reported Duchenne muscular dystrophy
  • Discontinued Chemotherapy-induced damage; Reperfusion injury; Type 2 diabetes mellitus

Most Recent Events

  • 27 Feb 2025 BGP-15 is still in phase-I trials for Familial dysautonomia in USA (Mitochon Technologies, pipeline - February 2025)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (PO, Capsule)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Familial dysautonomia in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top